The therapy of moderate and severe symptoms of interstitial cystitis (IC) recommended in the EU guidelines is not as effective. Intravesical administration of platelet-rich plasma (PRP) can improve the results of treatment of interstitial cystitis.

A single-center controlled randomized prospective trial that includes 85 women from 20 to 79 years old and with disease duration of 4.8±2.1 years. They were divided into 2 groups: 1 – 35 patients were treated with total of 5 procedures of cystoscopy with hydrodistension, each once in 2 weeks, 2 - 50 patients were treated with total of 5 intradetrusor PRP- injection into 20-22 points, each procedure was made once in 2 weeks (mean platelet concentration was 982х103/l). We assessed pain (VAS-scale), urgency and frequency (PUF-scale, IUS-scale), bladder diary, Global Response Assessment (GRA), bladder diary and bladder capacity before treatment,  after 1 and 12 months. Statistical analysis was made with Statistica 11.0 Software

All measurements are presented in table 1: 
Table 1. Evaluation of symptoms, bladder capacity and other signs before and after treatment

Symptoms and signs                                Before treatment                                                      After treatment
	                                                              I group/II group	                                    I group (n=35)	              II group (n=50)
		                                                                                                                              1m	   12m	                 1m	       12m.
VAS-scale, score                                           7,3*/7,6**	                                              3,7*	    6,0*	                 3,3**      3,5**
Frequency, number	                                 20*/21**	                                              13,9*	    16,0*	                 14,0**    12,2**
Daytime urination, number	                         16,8*/18**	                                              10,5*	    13,2*	                 11*	         10*
Night urination, number	                         3,2*/3**                                                       3,4*	     2,8*	                 3*	         2,2**
Urgency, score	                                         2,5*/2,6**	                                              1,6*	     2,0*	                 1,9**	1,6**
Bladder capacity, ml	                                 201,7*/178,2**	                                      302,3*   313,7*	         332,0**	347,5**
PUF scale, total score                          	 27,4*/24,6**                                               17,6*      22,9*	                 15,9**	13,7**
PUF scale, symptoms, score	                 18,1*/15,8**	                                               11,1*     14,5*	                  11,9**	9,5**
PUF scale  bothersomeness, score	         9,3*/8,8**	                                                6,5*	      8,4*	                  6,3**	4,3**
GRA, score	                                                     0/0	                                                        3,5*	       1,8*	                  4,3**	3,8**
Hunners lession, %	                                 100/100	                                                 –	       74,6	                     –	28,0
Notes: 
*   р<0,05 (Wilcoxon rank test)
** р<0,05 (Wilcoxon rank test)

PRP therapy has shown positive results of reducing the clinical picture in comparison with standard therapy. The introduction of platelet-rich plasma has a beneficial effect on the bladder mucosa, reducing the risk of Hunner's ulcers.

Standard therapy of IC leads to a significant decrease in the manifestations of the disease after 1 months. The same results have been demonstrated in PRP-group. However, there was worsening of symptoms in the 1st group after 12 months (but they don’t reach the initial values).  On the other hand, there were a stable pain symptoms by 12th month in the 2d group and improvement of other signs and symptoms (p<0,05) compared to initial values and 1 month after PRP – injection.

Continence 7S1 (2023) 100818
DOI: 10.1016/j.cont.2023.100818